Abiopharma

🔍 Wang Wenbei (Executive)

Company: Kanzhun Ltd (BZ)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Acquired 54,242 shares of Class A ordinary shares (Direct)
  Date: 2026-03-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 124,402.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 814 shares of Class A ordinary shares at $6.6914 per share (Direct)
  Date: 2026-03-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 123,588.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4
• Sold 54,242 shares of Restricted Share Unit (Derivative)
  Date: 2026-03-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 54,244.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: These Class A ordinary shares are held through American Depositary Shares ("ADS") of the issuer. Each ADS represents two Class A ordinary shares.
• F2: Represents Class A ordinary shares acquired in the form of ADS upon the vesting of restricted share units ("RSU") on March 30, 2026.
• F3: The shares were sold in a "sell-to-cover" transaction to cover tax withholding obligations in connection with the vesting and settlement of the RSUs.
• F4: Represents weighted average sales price. The shares were sold at prices ranging from $6.6914 to $6.6918. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F5: Each RSU represents a contingent right to receive one Class A ordinary share at settlement.
• F6: The RSUs vested and settled on March 30, 2026.